This strategic collaboration will leverage Lilly's deep expertise in metabolic diseases and Remedium's proprietary subcutaneously administered gene delivery system to develop and commercialize ...
BOSTON, Aug. 8, 2022 /PRNewswire/ -- Remedium Bio, a biotechnology company developing a lead candidate disease modifying treatment for Osteoarthritis (OA), today announced the acceptance of an ...
BOSTON, Sept. 15, 2021 /PRNewswire/ -- Remedium Bio, Inc., a biotechnology company developing novel gene therapies, is proud to announce it has entered into a Sponsored Research Agreement with Tufts ...
· Research focused on long-acting therapeutics based on Remedium's proprietary Prometheus platform · Multiple targets for the treatment of Obesity and Type 2 Diabetes BOSTON, MASSACHUSETTS / ACCESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback